Clin Mol Hepatol.
2025 Jan;31(1):e13-e14. 10.3350/cmh.2024.0682.
Letter to the editor on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”
- Affiliations
-
- 1Division of Pediatric Gastroenterology, Children’s Medical Center, Taichung Veterans General Hospital, Taichung, Taiwan
- 2Department of Post- Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung, Taiwan
- 3School of Medicine, Chung Shan Medical University, Taichung, Taiwan
- 4Evidence-based Medicine Center, Chung Shan Medical University Hospital, Taichung, Taiwan
- 5Library, Chung Shan Medical University Hospital, Taichung, Taiwan
- 6Department of Pharmacy, Chung Shan Medical University Hospital, Taichung, Taiwan
- 7Department and Graduate Institute of Business Administration, National Taiwan University, Taipei, Taiwan
- 8Department of Pharmacology, Chung Shan Medical University, Taichung, Taiwan
- 9Orthopedics Department, Chi-Mei Medical Center, Tainan, Taiwan
- KMID: 2563444
- DOI: http://doi.org/10.3350/cmh.2024.0682
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Atezolizumab and bevacizumab for hepatocellular carcinoma: How to approach salvage therapy for non-responders?: Editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Correspondence to letter to the editor on “Sorafenib vs. lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: a real-world study”
- Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study”
- Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/bevacizumab failure: A real-world study
- Complete response in hepatocellular carcinoma with lymph node metastasis by combination therapy of atezolizumab and bevacizumab: a case report
